Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 3/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | PSEN1 | P49768 | 1/20 | 0.34 |
| ▸ | PSEN2 | P49810 | 1/20 | 0.34 |
| ▸ | APH1B | Q8WW43 | 1/20 | 0.34 |
| ▸ | NCSTN | Q92542 | 1/20 | 0.34 |
| ▸ | APH1A | Q96BI3 | 1/20 | 0.34 |
| ▸ | PSENEN | Q9NZ42 | 1/20 | 0.34 |
| ▸ | BTK | Q06187 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 2/20 | 0.33 |
| ▸ | CTSL | P07711 | 1/20 | 0.33 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.33 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.33 |
| ▸ | APLNR | P35414 | 1/20 | 0.33 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.32 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.32 |
| ▸ | RELA | Q04206 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8284389 | 0.98 | CTSK (0.36) | CTSKMEN1MAPK1KMT2APSEN1 | |
| SCHEMBL571320 | 0.96 | CTSK (0.36) | CTSKMEN1MAPK1KMT2APSEN1 | |
| SCHEMBL571503 | 0.93 | CTSK (0.38) | CTSKMEN1MAPK1KMT2ABTK | |
| SCHEMBL21505991 | 0.86 | USP2 (0.33) | CTSKMEN1MAPK1KMT2AGAA | |
| SCHEMBL21505983 | 0.85 | MEN1 (0.37) | CTSKMEN1MAPK1KMT2APSEN1 | |
| SCHEMBL1666805 | 0.85 | USP2 (0.37) | CTSKMEN1MAPK1KMT2AGAA | |
| SCHEMBL22079845 | 0.84 | HCRTR2 (0.33) | CTSKMEN1MAPK1KMT2AHCRTR2 | |
| SCHEMBL21119394 | 0.83 | CTSK (0.33) | CTSKMEN1MAPK1KMT2APSEN1 | |
| SCHEMBL21488424 | 0.83 | BTK (0.32) | CTSKMEN1MAPK1KMT2APSEN1 | |
| SCHEMBL23802952 | 0.82 | CTSK (0.33) | CTSK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 126 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12612414-B2 | Nitrile SUMO inhibitors and uses thereof | CIT THERAPEUTICS, INC. (US) | 2026-04-28 | — | — | US | disclosed |
| EP-4482583-B1 | ZWITTERIONIC ANTIBACTERIAL COMPOUNDS | HOFFMANN LA ROCHE (CH) | 2026-04-01 | — | — | EP | disclosed |
| US-20240360148-A1 | NITRILE SUMO INHIBITORS AND USES THEREOF | CIT THERAPEUTICS LLC | 2024-10-31 | — | — | US | disclosed |
| EP-4373825-A1 | NITRILE SUMO INHIBITORS AND USES THEREOF | Suvalent Therapeutics, Inc. (US) | 2024-05-29 | — | — | EP | disclosed |
| US-20230210847-A1 | Substituted Alkynylene Compounds As Anticancer Agents | AURIGENE ONCOLOGY LTD (IN) | 2023-07-06 | — | — | US | disclosed |
| US-11633394-B2 | Substituted alkynylene compounds as anticancer agents | AURIGENE ONCOLOGY LIMITED (IN) | 2023-04-25 | — | — | US | disclosed |
| WO-2023004376-A1 | NITRILE SUMO INHIBITORS AND USES THEREOF | Suvalent Therapeutics, Inc. (US) | 2023-01-26 | — | — | WO | disclosed |
| US-20220340893-A1 | BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES | NUEVOLUTION A/S (DK) | 2022-10-27 | — | — | US | disclosed |
| US-10813939-B2 | Bromodomain inhibitor as adjuvant in cancer immunotherapy | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. (US) | 2020-10-27 | — | — | US | disclosed |
| US-10676484-B2 | Compositions and methods for treating leukemia | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2020-06-09 | — | — | US | disclosed |
| WO-2006129120-A9 | BENZOTRIAZEPINONE DERIVATIVES | JAMES BLACK FOUNDATION (GB) | 2007-03-22 | — | — | WO | disclosed |
| US-20070021484-A1 | Substituted N-cinnamyl benzamides | CHEMOCENTRYX, INC. (US) | 2007-01-25 | — | — | US | disclosed |
| WO-2007002842-A2 | SUBSTITUTED N-CINNAMYL BENZAMIDES | CHEMOCENTRYX, INC. (US) | 2007-01-04 | — | — | WO | disclosed |
| WO-2006129120-A2 | BENZOTRIAZEPINONE DERIVATIVES | JAMES BLACK FOUNDATION (GB) | 2006-12-07 | — | — | WO | disclosed |
| EP-1677599-A1 | HYDROXY PYRIDOPYRROLOPYRAZINE DIONE COMPOUNDS USEFUL AS HIV INTEGRASE INHIBITORS | Merck & Co., Inc. (US) | 2006-07-12 | — | — | EP | disclosed |
| US-20050282882-A1 | Diamines as modulators of chemokine receptor activity | CARTER PERCY | 2005-12-22 | — | — | US | disclosed |
| US-6974836-B2 | Diamines as modulators of chemokine receptor activity | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2005-12-13 | — | — | US | disclosed |
| WO-2005041664-A1 | HYDROXY PYRIDOPYRROLOPYRAZINE DIONE COMPOUNDS USEFUL AS HIV INTEGRASE INHIBITORS | MERCK & CO., INC. (US) | 2005-05-12 | — | — | WO | disclosed |
| US-20030125389-A1 | Beta-amino acid derivatives useful for the treatment of bacterial infections | VERSICOR, INC. | 2003-07-03 | — | — | US | disclosed |
| US-20030060459-A1 | Diamines as modulators of chemokine receptor activity | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2003-03-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030125389-A1 | Beta-amino acid derivatives useful for the treatment of bacterial infections | BCAT2, BCAT1, AADAT | CTSK 1235/4885MEN1 1491/4885MAPK1 2083/4885 |
| US-20230210847-A1 | Substituted Alkynylene Compounds As Anticancer Agents | MCL1, ROS1, MKI67 | CTSK 1858/4885MEN1 1649/4885MAPK1 1690/4885 |
| US-10813939-B2 | Bromodomain inhibitor as adjuvant in cancer immunotherapy | BRDT, BRD4, BRD1 | CTSK 1575/4885MEN1 4108/4885MAPK1 891/4885 |
| US-20050282882-A1 | Diamines as modulators of chemokine receptor activity | CCL11, CCR1, CCR2 | CTSK 2173/4885MEN1 2396/4885MAPK1 242/4885 |
| US-10676484-B2 | Compositions and methods for treating leukemia | MCL1, ABL1, FLT3 | CTSK 728/4885MEN1 2413/4885MAPK1 3917/4885 |
| US-11633394-B2 | Substituted alkynylene compounds as anticancer agents | MCL1, ROS1, MKI67 | CTSK 1858/4885MEN1 1649/4885MAPK1 1690/4885 |
| US-20240360148-A1 | NITRILE SUMO INHIBITORS AND USES THEREOF | SUMO1, SUMO3, SUMO2 | CTSK 2620/4885MEN1 2517/4885MAPK1 2130/4885 |
| US-12612414-B2 | Nitrile SUMO inhibitors and uses thereof | SUMO1, SUMO3, PSMB6 | CTSK 2087/4885MEN1 3270/4885MAPK1 2568/4885 |
| US-20030060459-A1 | Diamines as modulators of chemokine receptor activity | CCL11, CCR1, CCR2 | CTSK 2219/4885MEN1 2257/4885MAPK1 200/4885 |
| US-20070021484-A1 | Substituted N-cinnamyl benzamides | BRDT, BCCIP, NAT10 | CTSK 1378/4885MEN1 1537/4885MAPK1 4852/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.